Adavanced Glycated Endproducts and Development of CAD (AGENDA)

Shanghai Jiao Tong University School of Medicine

Status: Unknown

Conditions: Inflammation; Atherosclerosis

Study type: Observational

Funder types: Other

Identifiers

NCT02089360

RJH20140311

Details and patient eligibility

About

Blood sample is prospectively taken from consecutive patients underwent coronary angiogram in our center, after getting informed consent from the patients. Serum level of advanced glycation end products (AGEs) was measured and the clinical features of patients (including angiographic results) were entered into our database. Clinical follow-up was performed for all patients, and the relationship between AGEs and paitents' outcome were analyzed. Further intervention will be adjusted according to the results,including clinical and basic research in lab.

Full description

Serum levels of HMGB1, HMGB2, ADAM10, etc. will be measured in lab and animal studies will be designed to intervene the adverse interaction between abnormal serum concentration of AGEs, etc. and worse clinical results.

Enrollment: 10,000 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients underwent coronary angiogram for suspected coronary artery disease and potential percutaneous coronary intervention

Exclusion criteria

• patients underwent coronary angiogram for other reasons, including pre-surgery examination
• patients with severe co-morbidity, and life expectancy less than one-year